K Procházková,T Kazda,P Šlampa et al.
K Procházková et al.
Background: The patient's quality of life is an integral part of the evaluation of anticancer treatment. We can meet its evaluation mainly within the framework of clinical studies and research projects, but it is increasi...
Colorectal carcinoma - epidemiology, risk factors, prognostic bio markers [0.03%]
结直肠癌的流行病学、危险因素和预后生物标志物
M Hančinová,D Ondruš,M Ondrušová et al.
M Hančinová et al.
Background: In terms of epidemiology, colorectal carcinoma (CRC) represents one of the most prevalent tumors worldwide. Progress in research has translated into reduced mortality of the disease, but the trend of early ons...
A supportive programme for cancer patients based on knowledge of the neurobio logy of cancer [0.03%]
基于癌症神经生物学知识的癌症患者支持项目
B Mravec
B Mravec
Background: The importance of stress in cancer has been noted by physicians since the time of Galen. However, it is only in the last two decades that combined oncological and neuroscientific research has allowed to explor...
H Matsumoto,S Hasegawa,Y Maezawa et al.
H Matsumoto et al.
Background: Bronchial cysts (BCs) can be difficult to diagnose because of non-specific site of occurrence and heterogeneous density of cyst content in some patients. We present herein a BC case with such nonspecific findi...
Successful treatment of relapsed Waldenström's macroglobulinemia with proteasome inhibitors (bortezomib and subsequently ixazomib) in combination with rituximab and dexamethasone. A case report and review of the of proteasome inhibitors in Waldenström's… [0.03%]
成功采用蛋白酶体抑制剂治疗复发的瓦尔登斯特伦巨球蛋白血症：一例以硼替佐米和伊沙佐米联合利妥昔单抗及地塞米松治疗的病例报告及相关综述
Z Adam,M Krejčí,L Pour et al.
Z Adam et al.
Background: Waldenström's macroglobulinemia (WM) is a very rare disease with an incidence 10times lower than that of multiple myeloma. The incidence of WM is also significantly lower than that of the other CD20+ low-grad...
Chemotherapy as an optimal treatment option after failure of immunotherapy and targeted therapy in advanced and metastatic melanoma [0.03%]
免疫治疗和靶向治疗失败后的晚期黑色素瘤患者化疗作为优先选择疗法的思考
D Šulc
D Šulc
Background: Currently, there is no standard option that can be routinely recommended for the treatment of advanced melanoma after failure of modern immunotherapy and/or targeted therapy. Chemotherapy is an option, but its...
Current real-world evidence on characteristics and treatment patterns of lung cancer in the single cancer center in the Czech Republic - data from Masaryk Memorial Cancer Institute registry in 2018- 2022 [0.03%]
捷克单一癌症中心2018年至2022年肺癌患者特征和治疗模式的当前真实世界证据——来自马萨里克纪念癌症研究所注册的数据
O Bílek,I- Selingerová,M Kysela et al.
O Bílek et al.
Background: Lung cancer (LC) represents the leading cause of cancer-related deaths in the Czech Republic. Over the past decade, there have been notable advancements in LC treatment based on findings from controlled clinic...
The treatment combination of obinutuzumab, bendamustine and dexamethasone achieved a deeper response than the previous line of treatment in five patients with Waldenström's macroglobulinemia [0.03%]
奥比乌珠单抗、苯达莫司汀和地塞米松的联合疗法在五例瓦尔登斯特伦巨球蛋白血症患者中的疗效优于前期治疗方案
Z Adam,L Pour,M Krejčí et al.
Z Adam et al.
Background: Rituximab is already a standard part of the treatment of patients with Waldenström's macroglobulinemia. However, a small proportion of patients develop intolerance to rituximab during administration or the tr...
D Solil,P Dítě,B Kianička et al.
D Solil et al.
Background: Autoimmune pancreatitis (AIP) is a form of chronic pancreatitis that presents clinically with obstructive icterus, histologically with infiltration of pancreatic parenchyma by inflammatory cells leading to chr...
V Červeňák,Z Chovanec,A Berková et al.
V Červeňák et al.
Background: Lung cancer is one of the leading causes of death worldwide, with incidence and mortality significantly affected by population ageing and changes in the prevalence of risk factors. Lung nodules, which are ofte...